Shire

Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity
Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity
Fierce Pharma
Takeda
Shire
Allergan
chronic idiopathic constipation
Motegrity
Flag link:
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
Endpoints
Takeda
Shire
M&A
Flag link:
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Forbes
Shire
Takeda
R&D
M&A
Flag link:
Takeda ready to dismiss assets for a total $10bn
Takeda ready to dismiss assets for a total $10bn
GoinPharma
Takeda
Shire
M&A
Flag link:
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Fierce Pharma
Takeda
Shire
M&A
shareholders
Flag link:
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Endpoints
Takeda
shareholders
Japan
M&A
Shire
Europe
Flag link:
Takeda investors mount last-minute effort to stymie Shire deal: FT
Takeda investors mount last-minute effort to stymie Shire deal: FT
Fierce Pharma
Takeda
Shire
shareholders
M&A
Flag link:
With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan
With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan
Endpoints
Takeda
Shire
M&A
Christophe Weber
Flag link:
Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources
Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources
Channel News Asia
Takeda
Shire
M&A
Europe
Flag link:
Takeda CEO confident about Shire merger
Takeda CEO confident about Shire merger
Pharmaforum
Takeda
Shire
M&A
shareholders
Pharma CEOs
Christophe Weber
Flag link:
Positive quarter from Takeda, waiting for completion of Shire deal
Positive quarter from Takeda, waiting for completion of Shire deal
GoinPharma
Takeda
Shire
M&A
earnings
Flag link:
Takeda considering sale of OTC business in Europe ($11bn)
Takeda considering sale of OTC business in Europe ($11bn)
Bloomberg
Takeda
Shire
M&A
OTC
Flag link:
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Enpoints
Takeda
Shire
inflammatory bowel disease
IBD
ulcerative colitis
Crohn's Disease
M&A
SHP647
Flag link:
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
BrainStorm Cell Therapeutics
Allergan
Pfizer
Clovis Oncology
Acorda Therapeutics
Takeda
Agios Pharmaceuticals
Shire
Teva Pharmaceutical
AbbVie
Flag link:
Shire's drug for rare swelling disorder wins European panel green light
Shire's drug for rare swelling disorder wins European panel green light
Reuters
EMA
Europe
Shire
Takhzyro
HAE
Flag link:
Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout
Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout
Fierce Pharma
Shire
FDA
Takeda
M&A
Flag link:
FDA advisers back Shire constipation drug
FDA advisers back Shire constipation drug
Pharmaforum
FDA
Shire
advisory panels
prucalopride
CIC
chronic idiopathic constipation
Flag link:
Shire opens $1B plant to make rare disease drugs
Shire opens $1B plant to make rare disease drugs
Fierce Pharma
Shire
Georgia
drug manufacturing
Flag link:
Cost-effectiveness doubts could hit Shire’s Takhzyro launch
Cost-effectiveness doubts could hit Shire’s Takhzyro launch
EP Vantage
Shire
Cinryze
Takhzyro
drug pricing
hereditary angiodema
Flag link:
Disgruntled Takeda alums demand a window into $62B Shire buy
Disgruntled Takeda alums demand a window into $62B Shire buy
Fierce Pharma
Takeda
Shire
M&A
Flag link:

Pages